CorpDev.Org
Daily News for Dealmakers
Big Deal
Boston Scientific Acquires Penumbra In $14.5 Billion Bet To Dominate Thrombectomy
```html Boston Scientific Acquires Penumbra In $14.5 Billion Bet To Dominate Thrombectomy body { font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', 'Helvetica Neue', sans-serif; line-height: 1.6; color: #333; background-color: #fff; margin:...
Coca-Cola Drops Costa Coffee Sale After Private Equity Bids Fall Short: Report
Coca-Cola has scrapped plans to sell its Costa Coffee chain after private equity bids, including from TDR Capital and Bain Capital, fell below the beverage giant's £2 billion valuation target—roughly half the £3.9 billion it paid in 2019. ...
Toyota Motor Raises Take-Private Offer for Largest Subsidiary to $34 Billion: Strategic Pivot in EV Era
Toyota Motor Corporation has sweetened its **take-private offer** for its biggest subsidiary, **Denso Corporation**, boosting the bid to approximately $34 billion amid intensifying pressure to streamline operations and accelerate **electrification...
Netflix Reportedly Prepares All-Cash Bid For Warner Bros. As Paramount Turns Up Heat On Takeover Battle
```html Netflix is amending its Warner Bros. Discovery acquisition offer to an all-cash structure, signaling renewed commitment to a deal now valued at approximately $82.7 billion for the company's studios and streaming assets. The move comes as...
Blackstone to Offer Private Investments in Empower 401(k)s: Democratizing Alternatives for Retirement Savers
Blackstone, the world's largest alternative asset manager with over $1.2 trillion in assets under management, has partnered with Empower to integrate private equity, private credit, infrastructure, and real estate strategies into 401(k) plans via...
Explainers
Private Equity
International
International
Tech, Media & Telecom
Financial Services
Health & Life Sciences
GSK Acquires Rapt Therapeutics for $2.2 Billion to Secure Food Allergy Drug Ozureprubart
GSK agreed to acquire Rapt Therapeutics for $58 per share in cash, valuing the clinical-stage biotech at $2.2 billion in equity and requiring a net cash commitment of $1.9 billion after accounting for Rapt's cash position. Set and exceed synergy...
AstraZeneca CFO Outlines M&A Strategy Amid Surging Obesity Drug Demand
AstraZeneca's chief financial officer emphasized disciplined **M&A strategy** in pharmaceuticals, targeting bolt-on acquisitions to bolster its oncology and rare disease portfolios while eyeing opportunities in the **obesity market** projected to...
Sanofi Prepares Higher Bid for Ocular Therapeutix After $16/Share Rejection
Sanofi is revising its takeover offer for Ocular Therapeutix after the U.S. biotech rejected the French drugmaker's initial $16 per share proposal, according to recent filings and market reports. Ocular's shares trade at $11.07, implying a $2.36...
Boston Scientific Acquires Penumbra In $14.5 Billion Bet To Dominate Thrombectomy
```html Boston Scientific Acquires Penumbra In $14.5 Billion Bet To Dominate Thrombectomy body { font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', 'Helvetica Neue', sans-serif; line-height: 1.6; color: #333; background-color: #fff; margin:...
J&J Wins Partial Reversal of $1B Merger Milestone Loss: Implications for **Earnout Disputes** in Medtech M&A
Johnson & Johnson (NYSE: JNJ) secured a partial victory from Delaware's Supreme Court, overturning a key element of a $1 billion damages award tied to its 2019 $3.4 billion acquisition of surgical robotics firm Auris Health, with the case...
